Apolipoprotein E and Alzheimer's disease

Mahley, 2000, Apolipoprotein E: far more than a lipid, Annu Rev Genom Hum Genet, 1, 507, 10.1146/annurev.genom.1.1.507

Tudorache, 2017, Apolipoprotein E—a multifunctional protein with implications in various pathologies as a result of its structural features, Comput Struct Biotechnol J, 15, 359, 10.1016/j.csbj.2017.05.003

Utermann, 1977, Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man, Nature, 269, 604, 10.1038/269604a0

Chen, 2011, Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions, Proc Natl Acad Sci U S A, 108, 14813, 10.1073/pnas.1106420108

Pitas, 1987, Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins, Biochim Biophys Acta, 917, 148, 10.1016/0005-2760(87)90295-5

Huebbe, 2017, Evolution of human apolipoprotein E (APOE) isoforms: gene structure, protein function and interaction with dietary factors, Ageing Res Rev, 37, 146, 10.1016/j.arr.2017.06.002

McIntosh, 2012, The apolipoprotein E (APOE) gene appears functionally monomorphic in chimpanzees (Pan troglodytes), PLoS One, 7, 10.1371/journal.pone.0047760

Fullerton, 2000, Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism, Am J Hum Genet, 67, 881, 10.1086/303070

Singh, 2006, APOE distribution in world populations with new data from India and the UK, Ann Hum Biol, 33, 279, 10.1080/03014460600594513

Egert, 2012, ApoE genotype: from geographic distribution to function and responsiveness to dietary factors, Proc Nutr Soc, 71, 410, 10.1017/S0029665112000249

Hu, 2011, Does the geographical gradient of ApoE4 allele exist in China? A systemic comparison among multiple Chinese populations, Mol Biol Rep, 38, 489, 10.1007/s11033-010-0132-0

Farrer, 1997, Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium, JAMA, 278, 1349, 10.1001/jama.1997.03550160069041

Saunders, 1993, Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease, Neurology, 43, 1467, 10.1212/WNL.43.8.1467

Strittmatter, 1993, Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease, Proc Natl Acad Sci U S A, 90, 1977, 10.1073/pnas.90.5.1977

Corder, 1993, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science, 261, 921, 10.1126/science.8346443

Zannis, 1982, Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes, J Lipid Res, 23, 911, 10.1016/S0022-2275(20)38094-9

Zannis, 1981, Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification, Biochemistry, 20, 1033, 10.1021/bi00507a059

Wernette-Hammond, 1989, Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194, J Biol Chem, 264, 9094, 10.1016/S0021-9258(18)81907-X

Mahley, 1988, Apolipoprotein E: cholesterol transport protein with expanding role in cell biology, Science, 240, 622, 10.1126/science.3283935

Mahley, 1999, Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond, Curr Opin Lipidol, 10, 207, 10.1097/00041433-199906000-00003

Weisgraber, 1994, Apolipoprotein E: structure–function relationships, Adv Protein Chem, 45, 249, 10.1016/S0065-3233(08)60642-7

Weisgraber, 1996, Human apolipoprotein E: the Alzheimer's disease connection, FASEB J, 10, 1485, 10.1096/fasebj.10.13.8940294

Schneider, 1981, Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows, J Clin Invest, 68, 1075, 10.1172/JCI110330

Mahley, 1983, Lipoprotein receptors and cholesterol homeostasis, Biochim Biophys Acta, 737, 197, 10.1016/0304-4157(83)90001-1

Mahley, 1999, Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E, J Lipid Res, 40, 1, 10.1016/S0022-2275(20)33334-4

Getz, 2009, Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall, J Lipid Res, 50 Suppl, S156, 10.1194/jlr.R800058-JLR200

Wahrle, 2004, ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE, J Biol Chem, 279, 40987, 10.1074/jbc.M407963200

Herz, 2001, The LDL receptor gene family: (un)expected signal transducers in the brain, Neuron, 29, 571, 10.1016/S0896-6273(01)00234-3

Herz, 1994, Functions of the LDL receptor gene family, Ann N Y Acad Sci, 737, 14, 10.1111/j.1749-6632.1994.tb44298.x

Cooper, 1997, Hepatic uptake of chylomicron remnants, J Lipid Res, 38, 2173, 10.1016/S0022-2275(20)34932-4

Mahley, 2006, Putting cholesterol in its place: apoE and reverse cholesterol transport, J Clin Invest, 116, 1226, 10.1172/JCI28632

Zende, 2013, Apolipoprotein E gene polymorphism and its effect on plasma lipids in arteriosclerosis, J Clin Diagn Res, 7, 2149

Mahley, 1999, Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes, J Lipid Res, 40, 1933, 10.1016/S0022-2275(20)32417-2

Fredrickson, 1967, Fat transport in lipoproteins—an integrated approach to mechanisms and disorders, N Engl J Med, 276, 273, 10.1056/NEJM196702022760507

Davignon, 1988, Apolipoprotein E polymorphism and atherosclerosis, Arteriosclerosis, 8, 1, 10.1161/01.ATV.8.1.1

Eichner, 2002, Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review, Am J Epidemiol, 155, 487, 10.1093/aje/155.6.487

Menzel, 1983, Apolipoprotein E polymorphism and coronary artery disease, Arteriosclerosis, 3, 310, 10.1161/01.ATV.3.4.310

Stengard, 1995, Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men, Circulation, 91, 265, 10.1161/01.CIR.91.2.265

Nakashima, 1994, ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree, Arterioscler Thromb, 14, 133, 10.1161/01.ATV.14.1.133

Reddick, 1994, Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression, Arterioscler Thromb, 14, 141, 10.1161/01.ATV.14.1.141

Bellosta, 1995, Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice, J Clin Invest, 96, 2170, 10.1172/JCI118271

Fazio, 1997, Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages, Proc Natl Acad Sci U S A, 94, 4647, 10.1073/pnas.94.9.4647

Roher, 2003, Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease, Arterioscler Thromb Vasc Biol, 23, 2055, 10.1161/01.ATV.0000095973.42032.44

de Bruijn, 2014, Cardiovascular risk factors and future risk of Alzheimer's disease, BMC Med, 12, 130, 10.1186/s12916-014-0130-5

Eriksson, 2010, Nonstroke cardiovascular disease and risk of Alzheimer disease and dementia, Alzheimer Dis Assoc Disord, 24, 213, 10.1097/WAD.0b013e3181d1b99b

Brecht, 2004, Neuron-specific apolipoprotein E4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice, J Neurosci, 24, 2527, 10.1523/JNEUROSCI.4315-03.2004

Butterfield, 2020, Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease, Neurobiol Dis, 138, 104795, 10.1016/j.nbd.2020.104795

Dekroon, 2001, Synthesis and processing of apolipoprotein E in human brain cultures, Glia, 33, 298, 10.1002/1098-1136(20010315)33:4<298::AID-GLIA1028>3.0.CO;2-N

Harris, 2004, Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease, J Biol Chem, 279, 3862, 10.1074/jbc.M309475200

Horsburgh, 2000, Increased neuronal damage and apoE immunoreactivity in human apolipoprotein E, E4 isoform-specific, transgenic mice after global cerebral ischaemia, Eur J Neurosci, 12, 4309

Xu, 2006, Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus, J Neurosci, 26, 4985, 10.1523/JNEUROSCI.5476-05.2006

Lane-Donovan, 2016, Genetic restoration of plasma ApoE improves cognition and partially restores synaptic defects in ApoE-deficient mice, J Neurosci, 36, 10141, 10.1523/JNEUROSCI.1054-16.2016

Filippini, 2009, Anatomically-distinct genetic associations of APOE ε4 allele load with regional cortical atrophy in Alzheimer's disease, Neuroimage, 44, 724, 10.1016/j.neuroimage.2008.10.003

Boccardi, 2004, APOE and modulation of Alzheimer's and frontotemporal dementia, Neurosci Lett, 356, 167, 10.1016/j.neulet.2003.11.042

Agosta, 2009, Apolipoprotein E ε4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia, Proc Natl Acad Sci U S A, 106, 2018, 10.1073/pnas.0812697106

Becker, 2001, APOE genotype is a major predictor of long-term progression of disability in MS, Neurology, 57, 2148, 10.1212/WNL.57.11.2148

Fazekas, 2001, Apolipoprotein E ε4 is associated with rapid progression of multiple sclerosis, Neurology, 57, 853, 10.1212/WNL.57.5.853

Savettieri, 2003, Apolipoprotein E genotype does not influence the progression of multiple sclerosis, J Neurol, 250, 1094, 10.1007/s00415-003-0163-8

Chamelian, 2004, Six-month recovery from mild to moderate traumatic brain injury: the role of APOE-ε4 allele, Brain, 127, 2621, 10.1093/brain/awh296

Crawford, 2002, APOE genotype influences acquisition and recall following traumatic brain injury, Neurology, 58, 1115, 10.1212/WNL.58.7.1115

Gandy, 2012, APOE ε4 status and traumatic brain injury on the gridiron or the battlefield, Sci Transl Med, 4, 134ed4, 10.1126/scitranslmed.3004274

Benjamin, 1995, Effects of apolipoprotein E genotype on cortical neuropathology in senile dementia of the Lewy body and Alzheimer's disease, Neurodegeneration, 4, 443, 10.1006/neur.1995.0053

Li, 2004, Apolipoprotein E controls the risk and age at onset of Parkinson disease, Neurology, 62, 2005, 10.1212/01.WNL.0000128089.53030.AC

Martinez, 2005, Apolipoprotein E4 is probably responsible for the chromosome 19 linkage peak for Parkinson's disease, Am J Med Genet B Neuropsychiatr Genet, 136B, 72, 10.1002/ajmg.b.30196

McCarron, 1999, APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis, Neurology, 53, 1308, 10.1212/WNL.53.6.1308

Talha, 2020, Systematic review on apolipoprotein E: a strong genetic cause of hemorrhagic stroke, Mymensingh Med J, 29, 1026

Alberts, 1995, ApoE genotype and survival from intracerebral haemorrhage, Lancet, 346, 575, 10.1016/S0140-6736(95)91411-0

Brandon, 2018, APOE and Alzheimer's disease: neuroimaging of metabolic and cerebrovascular dysfunction, Front Aging Neurosci, 10, 180, 10.3389/fnagi.2018.00180

Kish, 1997, Brain energy metabolizing enzymes in Alzheimer's disease: alpha-ketoglutarate dehydrogenase complex and cytochrome oxidase, Ann N Y Acad Sci, 826, 218, 10.1111/j.1749-6632.1997.tb48473.x

Yamazaki, 2019, Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies, Nat Rev Neurol, 15, 501, 10.1038/s41582-019-0228-7

Swerdlow, 2018, Mitochondria and mitochondrial cascades in Alzheimer's disease, J Alzheim Dis, 62, 1403, 10.3233/JAD-170585

Morris, 2014, Is Alzheimer's disease a systemic disease?, Biochim Biophys Acta, 1842, 1340, 10.1016/j.bbadis.2014.04.012

Zhang, 2011, APP processing in Alzheimer's disease, Mol Brain, 4, 3, 10.1186/1756-6606-4-3

Wilkins, 2017, Amyloid precursor protein processing and bioenergetics, Brain Res Bull, 133, 71, 10.1016/j.brainresbull.2016.08.009

Schmechel, 1993, Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease, Proc Natl Acad Sci U S A, 90, 9649, 10.1073/pnas.90.20.9649

Bertram, 2007, Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database, Nat Genet, 39, 17, 10.1038/ng1934

Heinonen, 1995, Alzheimer pathology of patients carrying apolipoprotein E ε4 allele, Neurobiol Aging, 16, 505, 10.1016/0197-4580(95)00076-Q

Sanan, 1994, Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3, J Clin Invest, 94, 860, 10.1172/JCI117407

Strittmatter, 1993, Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease, Proc Natl Acad Sci U S A, 90, 8098, 10.1073/pnas.90.17.8098

Reiman, 2009, Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease, Proc Natl Acad Sci U S A, 106, 6820, 10.1073/pnas.0900345106

Lim, 2017, APOE genotype and early beta-amyloid accumulation in older adults without dementia, Neurology, 89, 1028, 10.1212/WNL.0000000000004336

Mishra, 2018, Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype, Brain, 141, 1828, 10.1093/brain/awy103

Jansen, 2015, Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis, JAMA, 313, 1924, 10.1001/jama.2015.4668

Bachmeier, 2013, A multifaceted role for apoE in the clearance of beta-amyloid across the blood–brain barrier, Neurodegener Dis, 11, 13, 10.1159/000337231

Deane, 2008, apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain, J Clin Invest, 118, 4002, 10.1172/JCI36663

Robert, 2017, Clearance of beta-amyloid is facilitated by apolipoprotein E and circulating high-density lipoproteins in bioengineered human vessels, Elife, 6, 10.7554/eLife.29595

Verghese, 2013, ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions, Proc Natl Acad Sci U S A, 110, E1807, 10.1073/pnas.1220484110

Wisniewski, 2020, APOE–amyloid interaction: therapeutic targets, Neurobiol Dis, 138, 104784, 10.1016/j.nbd.2020.104784

Castellano, 2011, Human apoE isoforms differentially regulate brain amyloid-β peptide clearance, Sci Transl Med, 3, 89ra57, 10.1126/scitranslmed.3002156

Huynh, 2017, Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-beta and other amyloidogenic proteins, J Lipid Res, 58, 824, 10.1194/jlr.R075481

Dafnis, 2010, An apolipoprotein E4 fragment can promote intracellular accumulation of amyloid peptide beta 42, J Neurochem, 115, 873, 10.1111/j.1471-4159.2010.06756.x

Lin, 2018, APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived brain cell types, Neuron, 98, 1141, 10.1016/j.neuron.2018.05.008

Koistinaho, 2004, Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides, Nat Med, 10, 719, 10.1038/nm1058

Basak, 2012, Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Aβ uptake and degradation by astrocytes, J Biol Chem, 287, 13959, 10.1074/jbc.M111.288746

Jiang, 2008, ApoE promotes the proteolytic degradation of Abeta, Neuron, 58, 681, 10.1016/j.neuron.2008.04.010

Cook, 2003, Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-ε4 allele, Am J Pathol, 162, 313, 10.1016/S0002-9440(10)63822-9

Miners, 2006, Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy, J Neuropathol Exp Neurol, 65, 1012, 10.1097/01.jnen.0000240463.87886.9a

Saido, 2012, Proteolytic degradation of amyloid beta-protein, Cold Spring Harb Perspect Med, 2, a006379, 10.1101/cshperspect.a006379

Hawkes, 2012, Disruption of arterial perivascular drainage of amyloid-beta from the brains of mice expressing the human APOE ε4 allele, PLoS One, 7, 10.1371/journal.pone.0041636

Achariyar, 2016, Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation, Mol Neurodegener, 11, 74, 10.1186/s13024-016-0138-8

Sanan, 1994, Apolipoprotein E associates with p3 amyloid peptide of Alzheimer's disease to form novel monofibrils, J Clin Invest, 94, 860, 10.1172/JCI117407

Liu, 2017, ApoE4 accelerates early seeding of amyloid pathology, Neuron, 96, 1024, 10.1016/j.neuron.2017.11.013

Huynh, 2017, Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of beta-amyloidosis, Neuron, 96, 1013, 10.1016/j.neuron.2017.11.014

Wang, 2018, Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector, Nat Med, 24, 647, 10.1038/s41591-018-0004-z

Nuriel, 2017, The endosomal–lysosomal pathway is dysregulated by APOE4 expression in vivo, Front Neurosci, 11, 702, 10.3389/fnins.2017.00702

Iqbal, 2010, Tau in Alzheimer disease and related tauopathies, Curr Alzheimer Res, 7, 656, 10.2174/156720510793611592

Naseri, 2019, The complexity of tau in Alzheimer's disease, Neurosci Lett, 705, 183, 10.1016/j.neulet.2019.04.022

Huang, 2010, Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease, Trends Mol Med, 16, 287, 10.1016/j.molmed.2010.04.004

Therriault, 2020, Association of apolipoprotein E ε4 with medial temporal tau independent of amyloid-β, JAMA Neurol, 77, 470, 10.1001/jamaneurol.2019.4421

Farfel, 2016, Association of APOE with tau-tangle pathology with and without beta-amyloid, Neurobiol Aging, 37, 19, 10.1016/j.neurobiolaging.2015.09.011

Tesseur, 2000, Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice, Am J Pathol, 156, 951, 10.1016/S0002-9440(10)64963-2

Zhao, 2020, APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's disease patient iPSC-derived cerebral organoids, Nat Commun, 11, 5540, 10.1038/s41467-020-19264-0

Shi, 2017, ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy, Nature, 549, 523, 10.1038/nature24016

Zhao, 2018, APOE ɛ2 is associated with increased tau pathology in primary tauopathy, Nat Commun, 9, 4388, 10.1038/s41467-018-06783-0

Harris, 2003, Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice, Proc Natl Acad Sci U S A, 100, 10966, 10.1073/pnas.1434398100

Huang, 2001, Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons, Proc Natl Acad Sci U S A, 98, 8838, 10.1073/pnas.151254698

Kloske, 2020, The important interface between apolipoprotein E and neuroinflammation in Alzheimer's disease, Front Immunol, 11, 754, 10.3389/fimmu.2020.00754

Atagi, 2015, Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2), J Biol Chem, 290, 26043, 10.1074/jbc.M115.679043

Bailey, 2015, The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E, J Biol Chem, 290, 26033, 10.1074/jbc.M115.677286

Wang, 2015, TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model, Cell, 160, 1061, 10.1016/j.cell.2015.01.049

Yeh, 2016, TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia, Neuron, 91, 328, 10.1016/j.neuron.2016.06.015

Guerreiro, 2013, TREM2 variants in Alzheimer's disease, N Engl J Med, 368, 117, 10.1056/NEJMoa1211851

Hooli, 2014, The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk, Neurology, 83, 1353, 10.1212/WNL.0000000000000855

Jonsson, 2013, Variant of TREM2 associated with the risk of Alzheimer's disease, N Engl J Med, 368, 107, 10.1056/NEJMoa1211103

Hsieh, 2009, A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia, J Neurochem, 109, 1144, 10.1111/j.1471-4159.2009.06042.x

Mazaheri, 2017, TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury, EMBO Rep, 18, 1186, 10.15252/embr.201743922

Takahashi, 2005, Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2, J Exp Med, 201, 647, 10.1084/jem.20041611

Ulrich, 2016, TREM2 function in Alzheimer's disease and neurodegeneration, ACS Chem Neurosci, 7, 420, 10.1021/acschemneuro.5b00313

Qiao, 2001, Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse, Eur J Neurosci, 14, 474, 10.1046/j.0953-816x.2001.01666.x

Lynch, 2003, APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response, J Biol Chem, 278, 48529, 10.1074/jbc.M306923200

Colton, 2002, APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress, Neurobiol Aging, 23, 777, 10.1016/S0197-4580(02)00016-7

Vitek, 2009, APOE genotype-specific differences in the innate immune response, Neurobiol Aging, 30, 1350, 10.1016/j.neurobiolaging.2007.11.014

Ulrich, 2018, ApoE facilitates the microglial response to amyloid plaque pathology, J Exp Med, 215, 1047, 10.1084/jem.20171265

Shi, 2019, Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model, J Exp Med, 216, 2546, 10.1084/jem.20190980

Dafnis, 2012, An apolipoprotein E4 fragment affects matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1 and cytokine levels in brain cell lines, Neuroscience, 210, 21, 10.1016/j.neuroscience.2012.03.013

Turner, 2016, Implications of MMP9 for blood brain barrier disruption and hemorrhagic transformation following ischemic stroke, Front Cell Neurosci, 10, 56, 10.3389/fncel.2016.00056

Nishitsuji, 2011, Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood–brain barrier model, J Biol Chem, 286, 17536, 10.1074/jbc.M111.225532

Yamazaki, 2020, ApoE (apolipoprotein E) in brain pericytes regulates endothelial function in an isoform-dependent manner by modulating basement membrane components, Arterioscler Thromb Vasc Biol, 40, 128, 10.1161/ATVBAHA.119.313169

Bell, 2012, Apolipoprotein E controls cerebrovascular integrity via cyclophilin A, Nature, 485, 512, 10.1038/nature11087

Main, 2018, Apolipoprotein E4 impairs spontaneous blood brain barrier repair following traumatic brain injury, Mol Neurodegener, 13, 17, 10.1186/s13024-018-0249-5

Mosconi, 2010, Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging, J Alzheim Dis, 20, 843, 10.3233/JAD-2010-091504

Morris, 2014, Impaired glycemia and Alzheimer's disease, Neurobiol Aging, 35, e23, 10.1016/j.neurobiolaging.2014.04.018

Silva, 2013, Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines, Hum Mol Genet, 22, 3931, 10.1093/hmg/ddt247

Kish, 1992, Brain cytochrome oxidase in Alzheimer's disease, J Neurochem, 59, 776, 10.1111/j.1471-4159.1992.tb09439.x

Parker, 1991, Cytochrome oxidase deficiency in Alzheimer's disease, Ann N Y Acad Sci, 640, 59, 10.1111/j.1749-6632.1991.tb00191.x

Parker, 1990, Cytochrome oxidase deficiency in Alzheimer's disease, Neurology, 40, 1302, 10.1212/WNL.40.8.1302

Chakravorty, 2019, Dysfunctional mitochondria and mitophagy as drivers of Alzheimer's disease pathogenesis, Front Aging Neurosci, 11, 311, 10.3389/fnagi.2019.00311

Jagust, 2012, Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging, J Neurosci, 32, 18227, 10.1523/JNEUROSCI.3266-12.2012

Johnson, 2017, Apolipoprotein E4 and insulin resistance interact to impair cognition and alter the epigenome and metabolome, Sci Rep, 7, 43701, 10.1038/srep43701

Arbones-Mainar, 2016, Metabolic shifts toward fatty-acid usage and increased thermogenesis are associated with impaired adipogenesis in mice expressing human APOE4, Int J Obes (Lond), 40, 1574, 10.1038/ijo.2016.93

Liu, 2015, Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain, J Neurosci, 35, 5851, 10.1523/JNEUROSCI.5180-14.2015

Zhao, 2017, Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes, Neuron, 96, 115, 10.1016/j.neuron.2017.09.003

Nakamura, 2009, Apolipoprotein E4 (1–272) fragment is associated with mitochondrial proteins and affects mitochondrial function in neuronal cells, Mol Neurodegener, 4, 35, 10.1186/1750-1326-4-35

Tambini, 2016, ApoE4 upregulates the activity of mitochondria-associated ER membranes, EMBO Rep, 17, 27, 10.15252/embr.201540614

Liang, 2021, ApoE4 (delta272–299) induces mitochondrial-associated membrane formation and mitochondrial impairment by enhancing GRP75-modulated mitochondrial calcium overload in neuron, Cell Biosci, 11, 50, 10.1186/s13578-021-00563-y

Yin, 2019, Apolipoprotein E regulates mitochondrial function through the PGC-1α–sirtuin 3 pathway, Aging (Albany NY), 11, 11148, 10.18632/aging.102516

James, 2012, Proteomic analysis of mitochondria in APOE transgenic mice and in response to an ischemic challenge, J Cerebr Blood Flow Metabol, 32, 164, 10.1038/jcbfm.2011.120

Schmukler, 2020, Altered mitochondrial dynamics and function in APOE4-expressing astrocytes, Cell Death Dis, 11, 578, 10.1038/s41419-020-02776-4

Yin, 2020, Effect of ApoE isoforms on mitochondria in Alzheimer disease, Neurology, 94, e2404, 10.1212/WNL.0000000000009582

Valla, 2010, Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene, J Alzheim Dis, 22, 307, 10.3233/JAD-2010-100129

Perkins, 2016, Altered energy metabolism pathways in the posterior cingulate in young adult apolipoprotein E ε4 carriers, J Alzheim Dis, 53, 95, 10.3233/JAD-151205

Mulica, 2021, Astrocyte–neuron metabolic crosstalk in neurodegeneration: a mitochondrial perspective, Front Endocrinol (Lausanne), 12, 668517, 10.3389/fendo.2021.668517

Williams, 2020, APOE alters glucose flux through central carbon pathways in astrocytes, Neurobiol Dis, 136, 104742, 10.1016/j.nbd.2020.104742

Wilkins, 2021, Bioenergetic and inflammatory systemic phenotypes in Alzheimer's disease APOE ε4-carriers, Aging Cell, 20, 10.1111/acel.13356

Wilkins, 2017, Platelet cytochrome oxidase and citrate synthase activities in APOE ε4 carrier and non-carrier Alzheimer's disease patients, Redox Biol, 12, 828, 10.1016/j.redox.2017.04.010

Ignatius, 1986, Expression of apolipoprotein E during nerve degeneration and regeneration, Proc Natl Acad Sci U S A, 83, 1125, 10.1073/pnas.83.4.1125

Li, 2010, An apolipoprotein E-mimetic stimulates axonal regeneration and remyelination after peripheral nerve injury, J Pharmacol Exp Therapeut, 334, 106, 10.1124/jpet.110.167882

Raman, 2020, Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which apolipoprotein E (APOE) contributes to Alzheimer's disease (AD) risk, Neurobiol Dis, 138, 104788, 10.1016/j.nbd.2020.104788

Yin, 2019, Apolipoprotein E affects in vitro axonal growth and regeneration via the MAPK signaling pathway, Cell Transplant, 28, 691, 10.1177/0963689718808736

Mahley, 2012, Apolipoprotein E sets the stage: response to injury triggers neuropathology, Neuron, 76, 871, 10.1016/j.neuron.2012.11.020

Strittmatter, 1994, Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype, Exp Neurol, 125, 163, 10.1006/exnr.1994.1019

Huang, 2012, Alzheimer mechanisms and therapeutic strategies, Cell, 148, 1204, 10.1016/j.cell.2012.02.040

Bellosta, 1995, Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth, J Biol Chem, 270, 27063, 10.1074/jbc.270.45.27063

Nathan, 1994, Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro, Science, 264, 850, 10.1126/science.8171342

Nathan, 1995, The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization, J Biol Chem, 270, 19791, 10.1074/jbc.270.34.19791

Johnson, 2014, Apolipoprotein E-low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner, Neurobiol Dis, 64, 150, 10.1016/j.nbd.2013.12.016

Fagan, 1996, Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein, J Biol Chem, 271, 30121, 10.1074/jbc.271.47.30121

Holtzman, 1995, Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line, Proc Natl Acad Sci U S A, 92, 9480, 10.1073/pnas.92.21.9480

Chen, 2010, ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling, Proc Natl Acad Sci U S A, 107, 12011, 10.1073/pnas.0914984107

Korwek, 2009, ApoE isoform-dependent changes in hippocampal synaptic function, Mol Neurodegener, 4, 21, 10.1186/1750-1326-4-21

Trommer, 2004, ApoE isoform affects LTP in human targeted replacement mice, Neuroreport, 15, 2655, 10.1097/00001756-200412030-00020

Bretsky, 1999, Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease, Alzheimer Dis Assoc Disord, 13, 216, 10.1097/00002093-199910000-00007

Poirier, 1993, Apolipoprotein E polymorphism and Alzheimer's disease, Lancet, 342, 697, 10.1016/0140-6736(93)91705-Q

Altmann, 2014, Sex modifies the APOE-related risk of developing Alzheimer disease, Ann Neurol, 75, 563, 10.1002/ana.24135

Corder, 2004, The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism, Ann N Y Acad Sci, 1019, 24, 10.1196/annals.1297.005

Payami, 1994, Alzheimer's disease, apolipoprotein E4, and gender, JAMA, 271, 1316, 10.1001/jama.1994.03510410028015

Gamache, 2020, Sex-dependent effect of APOE on Alzheimer's disease and other age-related neurodegenerative disorders, Dis Model Mech, 13, 10.1242/dmm.045211

He, 2009, A polymorphism of apolipoprotein E (APOE) gene is associated with age at natural menopause in Caucasian females, Maturitas, 62, 37, 10.1016/j.maturitas.2008.10.011

Meng, 2012, ApoE genotypes are associated with age at natural menopause in Chinese females, Age (Dordr), 34, 1023, 10.1007/s11357-011-9287-4

Gallart-Palau, 2016, Gender differences in white matter pathology and mitochondrial dysfunction in Alzheimer's disease with cerebrovascular disease, Mol Brain, 9, 27, 10.1186/s13041-016-0205-7

Operto, 2018, White matter microstructure is altered in cognitively normal middle-aged APOE-ε4 homozygotes, Alzheimer's Res Ther, 10, 48, 10.1186/s13195-018-0375-x

Mosconi, 2017, Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery, PLoS One, 12, 10.1371/journal.pone.0185926

Ding, 2013, Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer's mouse brain: implication for bioenergetic intervention, PLoS One, 8, 10.1371/journal.pone.0079977

Ding, 2013, Ovariectomy induces a shift in fuel availability and metabolism in the hippocampus of the female transgenic model of familial Alzheimer's, PLoS One, 8

Cheng, 2007, Estradiol replacement increases the low-density lipoprotein receptor related protein (LRP) in the mouse brain, Neurosci Lett, 417, 50, 10.1016/j.neulet.2007.02.030

De Marinis, 2008, Sex differences in hepatic regulation of cholesterol homeostasis, J Endocrinol, 198, 635, 10.1677/JOE-08-0242

Zhao, 2012, Continuous versus cyclic progesterone exposure differentially regulates hippocampal gene expression and functional profiles, PLoS One, 7

Ratnakumar, 2019, Estrogen activates Alzheimer's disease genes, Alzheimers Dement (N Y), 5, 906, 10.1016/j.trci.2019.09.004

Guimaraes, 2015, Spontaneous failure of the estrous cycle induces anxiogenic-related behaviors in middle-aged female mice, Physiol Behav, 147, 319, 10.1016/j.physbeh.2015.05.009

Yong, 2014, Reduced neuronal signaling in the ageing apolipoprotein-E4 targeted replacement female mice, Sci Rep, 4, 6580, 10.1038/srep06580

Farmer, 2021, APOE4 lowers energy expenditure in females and impairs glucose oxidation by increasing flux through aerobic glycolysis, Mol Neurodegener, 16, 62, 10.1186/s13024-021-00483-y

Williams, 2020, Therapeutic approaches targeting apolipoprotein E function in Alzheimer's disease, Mol Neurodegener, 15, 8, 10.1186/s13024-020-0358-9

Safieh, 2019, ApoE4: an emerging therapeutic target for Alzheimer's disease, BMC Med, 17, 64, 10.1186/s12916-019-1299-4

Hinrich, 2016, Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides, EMBO Mol Med, 8, 328, 10.15252/emmm.201505846

Donkin, 2010, ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice, J Biol Chem, 285, 34144, 10.1074/jbc.M110.108100

Cramer, 2012, ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models, Science, 335, 1503, 10.1126/science.1217697

Cummings, 2016, Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease, Alzheimer's Res Ther, 8, 4, 10.1186/s13195-016-0173-2

Ghosal, 2016, A randomized controlled study to evaluate the effect of bexarotene on amyloid-beta and apolipoprotein E metabolism in healthy subjects, Alzheimers Dement (N Y), 2, 110, 10.1016/j.trci.2016.06.001

Boehm-Cagan, 2016, ABCA1 agonist reverses the ApoE4-driven cognitive and brain pathologies, J Alzheim Dis, 54, 1219, 10.3233/JAD-160467

Kim, 2015, MicroRNA-33 regulates ApoE lipidation and amyloid-beta metabolism in the brain, J Neurosci, 35, 14717, 10.1523/JNEUROSCI.2053-15.2015

Jan, 2015, Direct intracerebral delivery of a miR-33 antisense oligonucleotide into mouse brain increases brain ABCA1 expression, Neurosci Lett, 598, 66, 10.1016/j.neulet.2015.05.007

Chernick, 2018, High-density lipoprotein mimetic peptide 4F mitigates amyloid-beta-induced inhibition of apolipoprotein E secretion and lipidation in primary astrocytes and microglia, J Neurochem, 147, 647, 10.1111/jnc.14554

Wang, 2007, An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction, Neuroscience, 144, 1324, 10.1016/j.neuroscience.2006.11.017

Sarantseva, 2009, Apolipoprotein E-mimetics inhibit neurodegeneration and restore cognitive functions in a transgenic Drosophila model of Alzheimer's disease, PLoS One, 4, 10.1371/journal.pone.0008191

Krishnamurthy, 2020, ApoE mimetic improves pathology and memory in a model of Alzheimer's disease, Brain Res, 1733, 146685, 10.1016/j.brainres.2020.146685

James, 2021, CN-105 in participants with acute supratentorial intracerebral hemorrhage (CATCH) trial, Neurocritical Care

Chen, 2012, Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons, J Biol Chem, 287, 5253, 10.1074/jbc.M111.276162

Kim, 2012, Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis, J Exp Med, 209, 2149, 10.1084/jem.20121274

Liao, 2014, Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis, J Neurosci, 34, 7281, 10.1523/JNEUROSCI.0646-14.2014

Liao, 2018, Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation, J Clin Invest, 128, 2144, 10.1172/JCI96429

Wadhwani, 2019, Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in Alzheimer disease, Ann Neurol, 85, 726, 10.1002/ana.25455

Hudry, 2013, Gene transfer of human APOE isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain, Sci Transl Med, 5, 212ra161, 10.1126/scitranslmed.3007000

Cabral, 2019, Exercise for brain health: an investigation into the underlying mechanisms guided by dose, Neurotherapeutics, 16, 580, 10.1007/s13311-019-00749-w

Koppel, 2018, Neuroketotherapeutics: a modern review of a century-old therapy, Neurochem Int, 117, 114, 10.1016/j.neuint.2017.05.019

Ridler, 2018, Exercise wards off Alzheimer disease by boosting neurogenesis and neuroprotective factors, Nat Rev Neurol, 14, 632

Strohle, 2015, Drug and exercise treatment of Alzheimer disease and mild cognitive impairment: a systematic review and meta-analysis of effects on cognition in randomized controlled trials, Am J Geriatr Psychiatr, 23, 1234, 10.1016/j.jagp.2015.07.007

Scarmeas, 2007, Mediterranean diet and Alzheimer disease mortality, Neurology, 69, 1084, 10.1212/01.wnl.0000277320.50685.7c

Sullivan, 2020, Influence of Western diet and APOE genotype on Alzheimer's disease risk, Neurobiol Dis, 138, 104790, 10.1016/j.nbd.2020.104790

Beal, 2010, Alzheimer disease: eating a combination of healthy foods lowers the risk of developing Alzheimer disease, Nat Rev Neurol, 6, 295, 10.1038/nrneurol.2010.56